Profile
ABVC NVO VRTX REGN MRNA SGEN
Company Name ABVC BioPharma, Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Moderna, Inc. Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $11.72M $564.11B $108.23B $104.90B $47.02B $43.15B
Employees 0.02K 66.02K 5.40K 13.68K 5.60K 3.26K
CEO Dr. Uttam Yashwant Patil Ph.D. Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. Stephane Bancel Mr. David R. Epstein B.Sc., M.B.A.
Ratings
ABVC NVO VRTX REGN MRNA SGEN
Quant Rating Score 2 5 5 5 2 3
Quant Rating Sell Strong Buy Strong Buy Strong Buy Sell Neutral
Trading
ABVC NVO VRTX REGN MRNA SGEN
Last Close $1.1 $128.66 $418.99 $968 $122.69 $228.74
High 52 $5.32 $199.54 $446.08 $993.35 $137.75 $228.9
Low 52 $0.38 $87.78 $323.57 $692.45 $69.51 $187.64
Price vs. 52 Week High -79.32 % -35.52 % -6.07 % -2.55 % -10.93 % -0.07 %
Price vs. 52 Week Low 189.47 % 46.57 % 29.49 % 39.79 % 76.51 % 21.9 %
Total Return
ABVC NVO VRTX REGN MRNA SGEN
1 Month Return -3.51 % 2.99 % 5.39 % 3.4 % 14.51 % 0 %
3 Month Return -16.67 % 6.16 % -0.93 % 1.53 % 40.36 % 0 %
6 Month Return 3.77 % 27.11 % 12.13 % 21.16 % 75.15 % 7.03 %
9 Month Return -49.31 % -29.34 % 20.61 % 22.07 % 22.35 % 17.3 %
YTD Return -5.17 % 24.37 % 2.97 % 10.21 % 23.37 % 0 %
1 Year Return 34.2 % -24.05 % 19.7 % 29.14 % -6.22 % 14.38 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ABVC NVO VRTX REGN MRNA SGEN
Dividend Yield Percentage (TTM) - 0.15 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.1 % 13.85 % 6.2 % -3.65 % -3.35 %
Dividend Per Share (TTM) - 0.2 % - - - -
Payout Ratio (TTM) - 47.03 % - - - -
Growth
ABVC NVO VRTX REGN MRNA SGEN
Asset Growth 51.63 % 30.35 % 25.23 % 13.23 % -28.74 % -1.21 %
Gross Profit Growth -126.07 % 32.32 % 9.25 % 6.49 % -85.12 % 22.93 %
Revenue Growth -84.28 % 31.26 % 10.17 % 7.76 % -64.94 % 24.65 %
Revenue 3 Year -85.65 % 90.51 % 59.87 % 55.67 % 2356.27 % 91.84 %
Revenue 5 Year 486.65 % 124.2 % 218.58 % 110.3 % 1070.62 % 215.48 %
Revenue 10 Year - 66.11 % 608.27 % 549.62 % 6447.35 % 494.04 %
EBIT Growth 45.64 % 37.11 % -12.94 % -14.6 % -145 % 10.13 %
Net Income Growth 35.54 % 50.71 % 8.96 % -8.87 % -156.37 % 9.51 %
Net Income 3 Yeari Growth Per Share 54.86 % 106.79 % 34.59 % 13.48 % -529.9 % -764.83 %
Net Income 5 Yeari Growth Per Share 31.36 % 133.86 % 70.33 % 74.02 % -160.17 % -276.93 %
Net Income 10 Yeari Growth Per Share -558.32 % 98.61 % 809.6 % 871.12 % -2046.03 % -624.16 %
Operating Income Growth 45.64 % 37.11 % -12.94 % -14.6 % -145 % 10.13 %
Operating Cash Flow Growth (CFG) 45.09 % 38.06 % -14.35 % -8.39 % -162.6 % 9.07 %
Operating 3 Year CFG 59.52 % 118.29 % 9.63 % 76.95 % -253.56 % -148.34 %
Operating 5 Year CFG -72.59 % 163.51 % 174.78 % 125.17 % -100.11 % -195.86 %
Operating 10 Year CFG -115.24 % 150.92 % 5187.08 % 713.56 % -4698.89 % -2622.09 %
EPS Growth 52.82 % 52.28 % 8.33 % -8.54 % -158.15 % 10.81 %
EPS Diluted Growth 52.82 % 52.37 % 8.35 % -9.03 % -161.39 % 10.81 %
Book Value Per Share 108.35 % 29 % 25.58 % 15.03 % -25.28 % -9.83 %
Share Holder 3 Year Equity Growth Per Share 16.91 % 75.22 % 104.06 % 137.56 % 439.94 % 33.92 %
Share Holder 5 Year Equity Growth Per Share 141.16 % 121.9 % 291.14 % 219.1 % 92.24 % 220.81 %
Share Holder 10 Year Equity Growth Per Share -98.73 % 49.62 % 1030.79 % 1286.9 % 1519.81 % 691.19 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - - - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth -19.76 % 4.74 % 44.1 % 0.06 % 3.58 % -23.28 %
Free Cash Flow Growth 45.68 % 9.17 % -16.47 % -17.11 % -183.5 % 3.67 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022
Profitability
ABVC NVO VRTX REGN MRNA SGEN
Gross Profit Margin TTM -103.12 % 84.65 % 86.91 % 87.16 % 21.77 % 75.4 %
Return on Assets TTM -58.66 % 29.87 % 16.81 % 11.22 % -35.67 % -20.64 %
Return on Equity TTM -182.32 % 91.82 % 23.61 % 15.15 % -41.83 % -28.06 %
Return on Capital Employed TTM -91.18 % 82.5 % 21.07 % 12.53 % -35.81 % -29.5 %
Net Income Per EBT TTM 82.27 % 79.81 % 84.31 % 95.44 % 124.28 % 101.53 %
EBT Per Ebit TTM 129.67 % 101.7 % 112.45 % 104.74 % 93.44 % 93.47 %
EBIT Per Revenue TTM -5390.35 % 45.03 % 41.62 % 29.46 % -99.69 % -34.37 %
Cash Flow To Debt Ratio TTM -172.1 % 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Receivables Turnover TTM 0.2 3.87 5.68 2.51 13.32 3.64
Payables Turnover TTM 2.74 2.88 0.42 2.51 22.04 2.52
Inventory Turnover TTM - 1.12 1.64 0.62 13.67 1.07
Fixed Asset Turnover TTM 1.74 % 248.64 % 685.54 % 310.02 % 186.78 % 471.71 %
Asset Turnover TTM 1.02 % 81.71 % 42.58 % 38.12 % 30.81 % 63.3 %
Operating Cash Flow Per Share TTM -0.53 20.95 15.27 43.96 -7.54 -2.87
Free Cash Flow Per Share TTM -0.53 11.28 14.17 36.87 -9.61 -3.73
Cash Per Share TTM 10.03 % 208.61 % 3939.31 % 9758.35 % 2235.6 % 657.5 %
Operating Cash Flow Sales Ratio TTM -2767.42 % 38.24 % 38.72 % 36.17 % -55.91 % -23.48 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 53.85 % 92.78 % 83.87 % 127.41 % 129.82 %
Cash Flow Coverage Ratios TTM -172.1 % 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Price To Free Cash Flows Ratio TTM -2.78 77.58 29.58 26.39 -12.8 -61.54
Price To Operating Cash Flows Ratio TTM -2.09 42.5 27.43 22.02 -16.26 -79.67
Price Cash Flow Ratio TTM -2.09 42.5 27.43 22.02 -16.26 -79.67
Income Statement (TTM)
ABVC NVO VRTX REGN MRNA SGEN
Revenue $0B $232.26B $9.84B $13.12B $6.75B $1.96B
Gross Profit $-0B $196.5B $8.58B $11.3B $2.06B $1.55B
Gross Profit Ratio -116.87% 84.6% 87.17% 86.16% 30.52% 79.1%
EBITDA $-0.01B $112.94B $3.93B $5.13B $-3.21B $-0.62B
Net Income $-0.01B $83.68B $3.62B $3.95B $-4.71B $-0.61B
EPS Diluted -2.43 18.62 13.89 34.77 -12.34 -3.3
Balance Sheet (MRQ)
ABVC NVO VRTX REGN MRNA SGEN
Long Term Debt $0B $20.53B $0.72B $2.7B $1.22B $0.04B
Total Liabilities $0.01B $207.93B $5.15B $7.11B $4.57B $0.87B
Total Equity $0.01B $106.56B $17.58B $25.97B $13.85B $2.8B
Total Investments $0B $17.5B $3.45B $13.51B $4.68B $1.42B
Total Debt $0B $27.01B $0.81B $2.7B $1.24B $0.04B
Total Assets $0.01B $314.49B $22.73B $33.08B $18.43B $3.67B
Cash Flow Statement (TTM)
ABVC NVO VRTX REGN MRNA SGEN
Net Income $-0.01B $83.68B $3.62B $3.95B $-4.71B $-0.61B
Inventory $0B $-7.42B $-0.32B $-0.27B $0.75B $-0.23B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0B $108.91B $3.54B $4.59B $-3.12B $-0.45B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.71B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 1.88
ABCL AbCellera Biologics Inc. 3.95
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.45
ABIO ARCA biopharma, Inc. 3.372
ABOS Acumen Pharmaceuticals, Inc. 3.57
ABSI Absci Corporation 5.14
ABUS Arbutus Biopharma Corporation 2.94
ABVX Abivax SA American Depositary Shares 14.15
ACAD ACADIA Pharmaceuticals Inc. 15.21
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.63
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.9186
ACHV Achieve Life Sciences, Inc. 4.53
ACIU AC Immune SA 2.35
ACLX Arcellx, Inc. 52.73
ACRV Acrivon Therapeutics, Inc. Common Stock 8.14
ACST Acasti Pharma Inc. 2.76
ACXP Acurx Pharmaceuticals, Inc. 2.02
ETFs With Exposure to ABVC
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 257.81
VXF Vanguard Extended Market Index Fund 0 171.23
IWC iShares Micro-Cap ETF 0 118.35
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 129.91
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 129.91
VEMPX Vanguard Extended Market Index InstlPlus 0 320.59
Unlock